7 unchanged sentences
3.2 Amended and Restated Bylaws of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 8-K filed on May 27, 2022)
−Removed: 4.1* Specimen Stock Certificate
−Removed: 10.1(1) Summary of Certain Compensation Arrangements for Executive Officers (incorporated by reference to the Registrant’s Form 8-K filed on June 6, 2022)
−Removed: 10.2 Principal Stockholders Agreement, dated as of December 22, 2021, by and among Coronado Topco, Inc., Quidel Corporation, Ortho Clinical Diagnostics Holdings plc and the Initial Carlyle Stockholder (as defined therein) (incorporated by reference to Annex B to the joint proxy statement/prospectus forming part of the Registration Statement on Form S-4 filed by Coronado Topco, Inc.
−Removed: with the SEC on January 31, 2022)
−Removed: 10.3++ Credit Agreement, dated May 27, 2022, by and among QuidelOrtho Corporation, each lender from time to time party thereto, each L/C Issuer (as defined therein), and Bank of America, N.A., as Administrative Agent and Swing Line Lender (incorporated by reference to Exhibit 10.2 to the Registrant’s Form 8-K filed on May 27, 2022)
+Added: 4.1 Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Form 10-Q filed on August 5, 2022)
10.1 Increase Joinder No.
−Removed: 1 , dated August 4, 2022, by and among QuidelOrtho Corporation, JPMorgan Chase Bank, N.A., as New Revolving Credit Lender, a Lender and a L/C Issuer, the Guarantors party thereto, and Bank of America, N.A., as the Administrative Agent
−Removed: 10.5(1) QuidelOrtho Corporation Amended and Restated 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Form 8-K filed on May 27, 2022)
−Removed: 10.6(1)* Form of Restricted Stock Unit Award Grant Notice
−Removed: 10.7(1)* Form of Restricted Stock Unit Award Grant Notice (Performance-based)
−Removed: 10.8(1)* Form of Restricted Stock Unit Award Grant Notice (Time-based)
−Removed: 10.9(1)* Form of Restricted Stock Unit Award Grant Notice (Deferred)
−Removed: 10.10(1)* Form of Notice of Grant of Nonqualified Stock Options and Option Agreement
−Removed: 10.11(1)* Form of Phantom Stock Unit Award Grant Notice
−Removed: 10.12(1) QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Form 8-K filed on May 27, 2022)
−Removed: 10.13(1) Employment Agreement, dated January 16, 2009, between Quidel Corporation and Douglas C.
−Removed: Bryant (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Quidel Corporation with the SEC on January 20, 2009)
−Removed: 10.14(1) Employment Offer Letter, dated June 5, 2008, between Quidel Corporation and Robert J.
−Removed: Bujarski (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Quidel Corporation with the SEC on June 6, 2008)
−Removed: 10.15(1) Employment Offer Letter, dated April 24, 2014, between Quidel Corporation and Werner Kroll (incorporated by reference to Exhibit 10.1 to the Form 10-Q for the quarter ended June 30, 2014 filed by Quidel Corporation with the SEC on July 24, 2014)
−Removed: 10.16(1) Enhanced Minimum Severance Letter, dated June 30, 2020, between Ortho-Clinical Diagnostics, Inc.
−Removed: and Joseph M.
−Removed: Busky (incorporated by reference to Exhibit 10.19 to the Form S-1 filed by Ortho Clinical Diagnostics Holdings plc with the SEC on January 4, 2021)
−Removed: 10.17(1) Severance Letter Agreement with Michael Iskra, dated May 2021 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed by Ortho Clinical Diagnostics Holdings plc with the SEC on May 25, 2021)
−Removed: 10.18(1) Form of Retention/Loyalty Bonus Opportunity Agreement (incorporated by reference to Exhibit 99.1 to the Form 8-K filed by Ortho Clinical Diagnostics Holdings plc with the SEC on January 18, 2022)
−Removed: 10.19(1) Amended and Restated Special Advisor Agreement, dated April 3, 2022, between Christopher Smith and QuidelOrtho Corporation (incorporated by reference to Exhibit 99.4 to the Form 8-K filed by Ortho Clinical Diagnostics Holdings plc with the SEC on April 7, 2022)
−Removed: 10.20(1) Letter Agreement, dated April 3, 2022, between Ortho Clinical Diagnostics Holdings plc and Christopher Smith (incorporated by reference to Exhibit 99.3 to the Form 8-K filed by Ortho Clinical Diagnostics Holdings plc with the SEC on April 7, 2022)
−Removed: 10.21(1) Form of Integration and Retention Bonus Letter (incorporated by reference to Exhibit 10.4 to the Form 8-K filed by Quidel Corporation with the SEC on February 4, 2022)
−Removed: 10.22(1) Form of Indemnification Agreement (incorporated by reference to Exhibit 10.10 to the Registrant’s Form 8-K filed on May 27, 2022)
−Removed: 10.23(1) Form of Change in Control Agreement (incorporated by reference to Exhibit 10.11 to the Registrant’s Form 8-K filed on May 27, 2022)
+Added: 1, dated August 4, 2022, by and among QuidelOrtho Corporation, JPMorgan Chase Bank, N.A., as New Revolving Credit Lender, a Lender and a L/C Issuer, the Guarantors party thereto, and Bank of America, N.A., as the Administrative Agent (incorporated by reference to Exhibit 10.4 to the Registrant’s Form 10-Q filed on August 5, 2022)
31.1* Certification by Principal Executive Officer of QuidelOrtho Corporation pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
2 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: 101 The following financial statements from the Registrant's Quarterly Report on Form 10-Q for the quarter ended July 3, 2022, formatted in Inline XBRL:
+Added: 101 The following financial statements from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended October 2, 2022, formatted in Inline XBRL:
(i) Consolidated Balance Sheets, (ii) Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive (Loss) Income, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags
−Removed: 104 The cover page from the Registrant's Quarterly Report on Form 10-Q for the quarter ended July 3, 2022, formatted in Inline XBRL (included as Exhibit 101)
+Added: 104 The cover page from the Registrant's Quarterly Report on Form 10-Q for the quarter ended October 2, 2022, formatted in Inline XBRL (included as Exhibit 101)
_________________________
1 unchanged sentence
The Registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.
−Removed: ++ Schedules and exhibits to the agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
−Removed: (1) Indicates a management plan or compensatory plan or arrangement.
* Filed herewith.
1 unchanged sentence
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: August 5, 2022 QUIDELORTHO CORPORATION
+Added: November 3, 2022 QUIDELORTHO CORPORATION
/s/ DOUGLAS C.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.